Iovance Biotherapeutics (IOVA) announced that Dan Kirby will join the Company’s executive leadership team in the newly created role of Chief ...

I would like to extend a warm welcome to Dan Kirby on behalf of the entire Iovance team,” stated Frederick Vogt, Ph.D., J.D., Interim President, Chief Executive Officer and board member of Iovance.

SAN CARLOS, Calif. - Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on novel cancer treatments, announced today the appointment of Dan Kirby (NYSE:KEX) as Chief ...

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic ...

In trading on Monday, shares of Iovance Biotherapeutics Inc (Symbol: IOVA) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $5.52 per share.

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio ...

Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for type 1 ...

CARMIEL, Israel, Feb. 4, 2025 /PRNewswire/ -- Protalix BioTherapeutics ... proteins produced by its proprietary ProCellEx ® plant cell based protein expression system, today announced that ...

Threads, too, has an option to create custom feeds. And now, you can share them with either a link or DM, or even by advertising them on your profile page. Creating a custom feed means freedom ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice.